KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Shares Issued (2017 - 2022)

Fulgent Genetics' Shares Issued history spans 7 years, with the latest figure at $12000.0 for Q4 2022.

  • For Q4 2022, Shares Issued fell 99.99% year-over-year to $12000.0; the TTM value through Dec 2023 reached $12000.0, down 61.29%, while the annual FY2025 figure was $1000.0, 98.04% down from the prior year.
  • Shares Issued for Q4 2022 was $12000.0 at Fulgent Genetics, up from $3000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $89.4 million in Q4 2021 and bottomed at -$75.6 million in Q3 2021.
  • The 5-year median for Shares Issued is $14000.0 (2022), against an average of $7.4 million.
  • The largest YoY upside for Shares Issued was 248441.18% in 2020 against a maximum downside of 3350.0% in 2020.
  • A 5-year view of Shares Issued shows it stood at $2000.0 in 2018, then skyrocketed by 1436500.0% to $28.7 million in 2019, then tumbled by 246.83% to -$42.2 million in 2020, then skyrocketed by 311.88% to $89.4 million in 2021, then tumbled by 99.99% to $12000.0 in 2022.
  • Per Business Quant, the three most recent readings for FLGT's Shares Issued are $12000.0 (Q4 2022), $3000.0 (Q2 2022), and $16000.0 (Q1 2022).